. Author manuscript; available in PMC: 2015 Oct 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):204–211. doi: 10.1097/QAI.0000000000000289

Table 4. Adjusted hazard ratio for non-AIDS-defining cancers by different HIV exposure metrics.

	HL			SCCA^a			HCC^b

	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Recent HIV RNA Load
Log₁₀, copies/mL	1.00	0.94-1.05	0.88	1.01	0.97-1.05	0.60	0.96	0.92-1.00	0.06
% undetectable HIV RNA
<20%	1			1			1
20-39%	0.85	0.56-1.29	0.44	1.05	0.79-1.40	0.73	1.27	0.93-1.74	0.13
40-59%	0.67	0.41-1.10	0.11	0.81	0.58-1.13	0.21	1.81	1.94-2.44	<0.01
60-79%	0.84	0.51-1.37	0.48	0.63	0.42-0.93	0.02	1.28	0.90-1.82	0.18
≥80%	0.62	0.37-1.02	0.06	0.64	0.44-0.93	0.02	1.39	0.98-1.99	0.07
HIV copy-years viremia
Log₁₀, copies × years/mL	1.22	1.06-1.40	0.005	1.36	1.21-1.52	<0.0001	1.02	0.93-1.13	0.67

HL=Hodgkin lymphoma; SCCA=Squamous cell carcinoma of the anus; HCC=Hepatocellular carcinoma. All adjusted regression models included the following additional variables: age at HIV diagnosis, race/ethnicity, use of illicit drugs, era of HIV diagnosis (pre-cART, early cART, late cART), Deyo modification of the Charlson comorbidity index, nadir CD4 count (prior to cART initiation), and recent CD4 count.

Regression model for SCCA also included condyloma.

Regression model for HCC also included hepatitis C and cirrhosis.